A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease
Status:
Withdrawn
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and efficacy of PF-01913539 in the
treatment of patients with mild-to-moderate Alzheimer's Disease. It is a 6-month study
enrolling 651 patients in Japan, Hong Kong, Korea, and Republic of China. All patients
completing the 6-month study will be eligible to receive PF-01913539 in an open-label
extension trial (B1451031).